Literature DB >> 9817168

Transforming growth factor-beta1 in sarcoidosis.

F Salez1, P Gosset, M C Copin, C Lamblin Degros, A B Tonnel, B Wallaert.   

Abstract

Transforming growth factor-beta (TGF-beta) is a cytokine that promotes extracellular matrix accumulation and inhibits matrix degradation. Although the natural course of sarcoidosis is usually favourable, granuloma healing in the lung may result in pulmonary fibrosis and respiratory impairment in some patients. In this study TGF-beta1 was evaluated in bronchoalveolar lavage (BAL) fluid and culture supernatants of alveolar macrophages (AM) from 73 patients with biopsy-proven sarcoidosis. Disease activity was defined when patients recently developed or increased symptoms (cough, dyspnoea, systemic symptoms) and/or demonstrated increasing opacities on chest radiography. Pulmonary function tests were performed in all patients including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), total lung capacity (TLC) and the diffusing capacity of the lung for carbon monoxide (DL,CO). Fourteen patients with idiopathic pulmonary fibrosis (IPF) and 14 healthy subjects were investigated as a control group. Immunohistochemistry was used to evaluate the cell distribution of TGF-beta1 on lung specimens. TGF-beta1 levels in BAL and in AM supernatants were not different between sarcoidosis and healthy subjects, whereas they were markedly increased in IPF. However, the TGF-beta1 level was significantly increased in BAL fluid but not in AM supernatants from sarcoidosis with altered lung function, compared with patients with normal lung function. The TGF-beta1 level in BAL was increased in active sarcoidosis but this increased level was mainly related to the higher level observed in patients with altered lung function. TGF-beta1 levels in BAL correlated significantly with the lymphocyte percentage. TGF-beta1 staining assessed by immunohistochemistry was intense in epithelioid histiocytes comprising non-necrotizing granuloma and in bronchiolar epithelial cells, in hyperplastic type II pneumocytes and occasionally in AM. This study supports the hypothesis that overproduction of transforming growth factor-beta1 is associated with functional impairment in patients with pulmonary sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817168     DOI: 10.1183/09031936.98.12040913

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

Review 1.  Genetics of sarcoidosis: candidate genes and genome scans.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki
Journal:  Proc Am Thorac Soc       Date:  2007-01

2.  Antifibrotic role of HGF in sarcoidosis.

Authors:  Martin Faehling; Martin Hetzel; Diana Anders; Gerlinde Trischler; Max Bachem
Journal:  Lung       Date:  2012-02-05       Impact factor: 2.584

3.  Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis.

Authors:  Felix Chua; Sarah E Dunsmore; Peter H Clingen; Steven E Mutsaers; Steven D Shapiro; Anthony W Segal; Jürgen Roes; Geoffrey J Laurent
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

5.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

Review 6.  The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques.

Authors:  Hasib Ahmadzai; Denis Wakefield; Paul S Thomas
Journal:  Inflammopharmacology       Date:  2011-02-13       Impact factor: 4.473

Review 7.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

8.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

9.  Increased interleukin-13 expression in patients with sarcoidosis.

Authors:  H-P Hauber; D Gholami; A Meyer; A Pforte
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 10.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.